ITUS is an early stage biotechnology company. Through its subsidiary, Anixa Diagnostics Corporation, Co. develops a platform for non-invasive blood tests for the early detection of cancer. That platform is called Cchek™. Co.'s CchekO™ cancer detection platform measures a patient's immune response to a malignancy by detecting the presence, absence, and quantity of certain immune cells that exist in and around a tumor and that enter the blood stream. Co. is also engaged in limited patent licensing activities in the area of encrypted audio/video conference calling. We show 15 historical shares outstanding datapoints in our ITUS shares outstanding history coverage, used to compute ITUS market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ITUS market cap history over the course of time is important for investors
interested in comparing ITUS's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ITUS versus a peer is one thing; comparing
ITUS market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ITUS can fluctuate over the course of history.
With this page we aim to empower investors researching ITUS by allowing them to research the ITUS market cap history. |
Free ITUS Email Alerts:
Video: The Importance of Market Cap
